Coming Soon
This content is currently not available. Please check back again soon.
Skip to main content
IMPORTANT SAFETY INFORMATION
Risk From Radiation Exposure
- PLUVICTO contributes to a patient’s long-term cumulative radiation exposure, which is associated with an increased risk for cancer.
- Minimize radiation exposure to patients, medical personnel, and others during and after treatment with PLUVICTO consistent with institutional practices, patient treatment procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection.
- Ensure patients increase oral fluid intake and advise them to void as often as possible to reduce bladder radiation...
Indications
PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer.
PLUVICTO is indicated for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and
- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy.
Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION